Table 3.

Parameter estimates for the NT-proBNP model

Parameter	Units	Estimate	95% CI from bootstrap	Shrinkage (%)
TVkin	pg/mL/day	77.4	46.4–126.9
[NT-proBNP]baseline	pg/mL	3140	2857–3482
${\theta }_{k_{\text{in}},\text{NT-proBNP}}$		0.347	0.304–0.405
kout_max	day–1	0.157	0.086–0.330
Emax		0.95 FIX
EC50	pg/mL	439	233–792
ATRT	L/h/mg	0.0176	0.024–0.360
${\omega }^2$ (IIV kin)		0.163	0.104–0.240	22.2
${\omega }^2$ (IIV [NT-proBNP]baseline)		0.953	0.814–1.089	3.0
σ2 (additive residual error)		0.145	0.129–0.161	15.4

ATRT parameter describing the inhibition of k_in by the 24-h area under the plasma concentration–time curve of vericiguat through a linear model, [NT-proBNP]_baseline baseline plasma concentration of NT-proBNP, CI confidence interval, EC₅₀ concentration at which the inhibition of k_{out_max} is half of its maximum extent, E_max parameter describing the maximum extent that k_out can be reduced through an increase in concentration of NT-proBNP, TVk_in zero-order rate constant describing the production of NT-proBNP in a subject with a median baseline concentration of NT-proBNP in the absence of treatment with vericiguat, k_{out_max} parameter describing the maximum value of the first-order rate constant for elimination of NT-proBNP, NT-proBNP N-terminal pro-B-type natriuretic peptide, σ² variance of additive residual error in concentration of NT-proBNP when modeled after logarithmic transformation, ω² (IIV [NT-proBNP]_baseline) variance of exponential inter-individual variability in [NT-proBNP]_baseline, ω² (IIV k_in) variance of exponential inter-individual variability in kin, ${\theta }_{k_{\mathrm{in},\mathrm{NT}-\mathrm{proBNP}}}$ parameter describing the influence of [NT-proBNP]_baseline on k_in